Use of Patolamooladi churna along with Devdarvyadi pradeha in ascites of hepatic cirrhosis origine.

A Clinical Study Of YAKRITJANYA JALODARA W.S.R. TO ASCITES OF HEPATIC CIRRHOSIS Origin With Trial Drug PATOLAMOOLADI CHURNA ALONG WITH DEVDARVYADI PRADEHA - An Open Labelled Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082977

Enrollment

Registered

2025-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K740- Hepatic fibrosis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients having ascites due to Hepatic Cirrhosis origin. Chronicity less than 1 year. Uncomplicated cases of Yakritjanya Jalodara. Patients willing to participate in trial.

Exclusion criteria

Exclusion criteria: Hb less than 5 g per dl Pancreatic origin cirrhosis AIDS Congestive Cardiac Failure, Congestive Pericarditis, Other Cardiac disorders T.B. Nephrotic Syndrome Carcinoma Hepatic encephalopathy Diabetic ketoacidosis Hepatitis B and Hepatitis C Acute and Chronic Renal Failure Acute pancreatitis Piles History of Recurrent Gastric and Esophageal Variceal Rupture and Hematemesis Associated with any other serious systemic disease or complications, which leads to fatal conditions will be excluded.

Design outcomes

Primary

Measure	Time frame
It is expected that the trial drugs will break the pathogenesis of Yakritjanya Jalodara and thus will be effective in the management of Yakritjanya Jalodara(Ascites of Hepatic cirrhosis origin) by give relief in subjective parameter like Distention of abdomen, Pedal edema, Anorexia, Weakness, Nausea and vomiting, Respiratory distress and objective parameters like AST, ALT, Serum bilirubin, serum alkaline phosphatase, A:G ratio, PT/INR.Timepoint: 28 days	—

Measure

Time frame

It is expected that the trial drugs will break the pathogenesis of Yakritjanya Jalodara and thus will be effective in the management of Yakritjanya Jalodara(Ascites of Hepatic cirrhosis origin) by give relief in subjective parameter like Distention of abdomen, Pedal edema, Anorexia, Weakness, Nausea and vomiting, Respiratory distress and objective parameters like AST, ALT, Serum bilirubin, serum alkaline phosphatase, A:G ratio, PT/INR.Timepoint: 28 days

—

Secondary

Measure	Time frame
The drug will improve the quality of life & thus will act as disease-modifying agent for Yakritjanya Jalodara(Ascites of Hepatic cirrhosis origin) by restoring normal function of liver, improve digestion, provide relief in generalised weakness, edema etc symptomsTimepoint: 42 days	—

Countries

India

Contacts

Public ContactParthkumar Patel

Goverment Akhandanand Ayurveda college, Bhadra, Ahmedabad, Gujarat

surendraasoni@gmail.com9408441150

Outcome results